This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Mediware Enters Into Merger Agreement With Thoma Bravo

LENEXA, Kan., Sept. 12, 2012 (GLOBE NEWSWIRE) -- Mediware Information Systems, Inc. (Nasdaq:MEDW), a leading provider of clinical software solutions, today announced it has entered into a definitive merger agreement to be acquired by leading private equity investment firm Thoma Bravo, LLC in a transaction valued at approximately $195 million. Under the terms of the agreement, pending shareholder approval, Mediware shareholders will receive $22.00 in cash for each share of Mediware common stock. This represents an approximately 40 percent premium over the Company's most recent closing price.

"Mediware has sustained consistent revenue and earnings growth over the past five years by focusing on effectively expanding its product portfolios to new areas of care," said Thomas Mann, Mediware's president and chief executive officer. "The acquisition by Thoma Bravo recognizes this performance and validates our belief that Mediware is positioned for continued growth and profitability in the future. We look forward to continued investments in our products and people, and to working with Thoma Bravo as we expand our leadership role in healthcare technology."

"Mediware's reputation as a best-in-class provider of software systems that enhance healthcare organizations' ability to provide excellent, yet cost-effective care, is well-deserved," said Thoma Bravo managing partner Scott Crabill. "We see strong growth potential as more and more organizations seek technology solutions to improve the management of their clinical, regulatory and financial operations."

"Thoma Bravo is excited to partner with Mediware's existing management team to continue to expand the company's leadership position in the markets it serves," added Seth Boro, partner at Thoma Bravo.  "We look forward to building on the company's reputation for first-class products, strategic acquisitions, and strong customer service."

The transaction is subject to customary closing conditions, including requisite regulatory approvals and the approval of Mediware shareholders. The Mediware board of directors has unanimously approved the agreement and recommends that Mediware's shareholders approve the transaction. The transaction is not subject to a financing condition. Mediware expects the transaction to close before December 31, 2012. At closing, Thoma Bravo will acquire 100 percent of Mediware's outstanding shares.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.99 -0.02%
FB $99.54 -0.21%
GOOG $678.11 -0.68%
TSLA $148.25 0.18%
YHOO $26.82 -0.85%


Chart of I:DJI
DOW 16,014.38 -12.67 -0.08%
S&P 500 1,852.21 -1.23 -0.07%
NASDAQ 4,268.7630 -14.99 -0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs